Search hospitals > Massachusetts > Burlington
Lahey Hospital and Medical Center
Claim this profileBurlington, Massachusetts 01803
Global Leader in Parotid Gland Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cervical Adenocarcinoma
472 reported clinical trials
33 medical researchers
Summary
Lahey Hospital and Medical Center is a medical facility located in Burlington, Massachusetts. This center is recognized for care of Parotid Gland Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Cervical Adenocarcinoma and other specialties. Lahey Hospital and Medical Center is involved with conducting 472 clinical trials across 637 conditions. There are 33 research doctors associated with this hospital, such as Corrine Zarwan, MD, Brendan Connell, Paul J. Hesketh, and Ragisha Gopalakrishnan.Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
Top PIs
Corrine Zarwan, MDLahey Hospital and Medical Center8 years of reported clinical research
Expert in Parotid Gland Cancer
Studies Breast Cancer
16 reported clinical trials
47 drugs studied
Brendan ConnellLahey Hospital and Medical Center5 years of reported clinical research
Studies Parotid Gland Cancer
Studies Lung Cancer
14 reported clinical trials
38 drugs studied
Paul J. HeskethLahey Hospital and Medical Center5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
13 reported clinical trials
21 drugs studied
Ragisha GopalakrishnanMount Sinai Medical Center1 year of reported clinical research
Studies Breast Cancer
Studies Colorectal Cancer
7 reported clinical trials
15 drugs studied
Clinical Trials running at Lahey Hospital and Medical Center
Breast Cancer
Lung Cancer
Bladder Cancer
Breast cancer
Non-Small Cell Lung Cancer
Kidney Cancer
Parotid Gland Cancer
Bladder Carcinoma
Acute Respiratory Distress Syndrome
Prostate Cancer
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Lahey Hospital and Medical Center?
Where is Lahey Hospital and Medical Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does Lahey Hospital and Medical Center accept?
What awards or recognition has Lahey Hospital and Medical Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.